Table 2.

Demographic, clinical and serological features of pSS patients with sensory and sensorimotor neuropathy in comparison to patients without PNS involvement.

	No PNS involvement (N. 1633)	Pure sensory neuropathy (N. 25)	p value	Sensorimotor polineuropathy (N. 35)	p value
Gender (male)	4.4%	4.0%	1.000	11.4%	0.069
Age at diagnosis, median (range), years	53 (10-86)	49 (21-80)	0.959	52 (38-79)	0.339
Disease duration, median (range), years	4 (0-45)	8 (0-26)	0.017	4 (0-32)	0.373
Parotid swelling	29.4%	8.0%	0.024	34.3%	0.659
Purpura	7.3%	16.0%	0.110	25.7%	0.0001
Raynaud phenomenon	22.4%	32.0%	0.370	28.6%	0.510
Other organ involvement	37.8%	100%	0.0001	97.1%	0.0001
Lymphoma	4.2%	8.0%	0.285	5.7%	0.656
Leukopenia	24.2%	20.0%	0.815	48.6%	0.002
Hypocomplementemia	19.2%	32.0%	0.175	45.7%	0.0001
Low C3	16.4%	21.7%	0.568	26.5%	0.184
Low C4	10.5%	21.7%	0.090	35.3%	0.0001
Hypergammaglobulinemia	43.7%	44.0%	1.000	45.7%	0.950
Monoclonal gammopathy	6.7%	16.0%	0.085	11.4%	0.293
Antinuclear antibodies	87.0%	100%	0.064	88.6%	1.000
Anti-SSA/Ro	66.1%	80.0%	0.200	68.6%	0.904
Anti-SSB/La	32.2%	44.0%	0.301	34.3%	0.939
Rheumatoid factor	45.8%	40.0%	0.707	51.4%	0.625
Cryoglobulins	3.8%	12.0%	0.072	22.9%	0.0001
Other autoantibodies	16.27%	24.0%	0.445	37.1%	0.002
Glucocorticoids	39.8%	60.9%	0.067	81.8%	0.0001
Immunosuppressants	16.6%	47.8%	0.0001	57.6%	0.0001
Hydroxychloroquine	46.4%	56.5%	0.440	45.5%	1.000

Significant results, as described in the Methods, are shown in bold.